Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Simvastatin
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Medical uses== The primary uses of simvastatin are to treat [[dyslipidemia]] and to prevent atherosclerosis-related complications such as stroke and heart attacks in those who are at high risk.<ref name="AHFS2015"/> It is recommended to be used as an addition to a low-cholesterol diet.<ref name="AHFS2015"/> In heart protection studies, simvastatin showed the ability to lower LDL cholesterol by about 1·5 mmol/L, which resulted in substantial reductions in mortality rates. Simvastatin also reduced the numbers of other events like heart attacks, strokes, and revascularizations and MI significantly.<ref name="Pedersen_2004">{{cite journal | vauthors = Pedersen TR, Tobert JA | title = Simvastatin: a review | journal = Expert Opinion on Pharmacotherapy | volume = 5 | issue = 12 | pages = 2583–96 | date = December 2004 | pmid = 15571475 | doi = 10.1517/14656566.5.12.2583 | s2cid = 36911054 }}</ref> The [[Heart Protection Study]] evaluated the effects of simvastatin in people with risk factors including existing cardiovascular disease, diabetes, or stroke, but having relatively low LDL cholesterol. In this trial, which lasted 5.4 years, overall mortality was reduced by 13% and cardiovascular mortality was reduced by 18%. People receiving simvastatin experienced 38% fewer nonfatal heart attacks and 25% fewer strokes.<ref name="Zocor PI">{{cite web|title=Zocor Full Prescribing Information|url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019766s093lbl.pdf|url-status=dead|archive-url=https://web.archive.org/web/20151208172832/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/019766s093lbl.pdf|archive-date=8 December 2015|publisher=U.S. [[Food and Drug Administration]] (FDA)}}</ref> Statins in general have been proposed as beneficial in reducing the progression of Age-related Macular Degeneration (AMD).<ref name="pmid30469381">{{cite journal | vauthors = Roizenblatt M, Naranjit N, Maia M, Gehlbach PL | title = The Question of a Role for Statins in Age-Related Macular Degeneration | journal = International Journal of Molecular Sciences | volume = 19 | issue = 11 | date = November 2018 | page = 3688 | pmid = 30469381 | pmc = 6274767 | doi = 10.3390/ijms19113688 | url = | doi-access = free }}</ref> Multiple observational studies have been conducted<ref>{{cite journal | vauthors = Al-Holou SN, Tucker WR, Agrón E, Clemons TE, Cukras C, Ferris FL, Chew EY | title = The Association of Statin Use with Age-Related Macular Degeneration Progression: The Age-Related Eye Disease Study 2 Report Number 9 | journal = Ophthalmology | volume = 122 | issue = 12 | pages = 2490–6 | date = December 2015 | pmid = 26435335 | pmc = 4658271 | doi = 10.1016/j.ophtha.2015.08.028 }}</ref><ref>{{cite journal | vauthors = Barbosa DT, Mendes TS, Cíntron-Colon HR, Wang SY, Bhisitkul RB, Singh K, Lin SC | title = Age-related macular degeneration and protective effect of HMG Co-A reductase inhibitors (statins): results from the National Health and Nutrition Examination Survey 2005-2008 | journal = Eye | volume = 28 | issue = 4 | pages = 472–80 | date = April 2014 | pmid = 24503725 | pmc = 3983650 | doi = 10.1038/eye.2014.8 }}</ref> to analyse the benefits of statin use in delaying the progression of AMD but have resulted in conflicting outcomes. Given the current available information, simvastatin should not be recommended solely for the treatment of AMD.{{cn|date=January 2025}}
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)